{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:27:21Z","timestamp":1792643241317,"version":"4.5.0"},"reference-count":61,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s383138","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:20:22Z","timestamp":1722385222000},"page":"3415-3428","source":"Crossref","is-referenced-by-count":36,"title":["Insights on Nefecon\u00ae, a Targeted-Release Formulation of Budesonide and Its Selective Immunomodulatory Effects in Patients with IgA Nephropathy"],"prefix":"10.2147","volume":"Volume 18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9063-7229","authenticated-orcid":true,"given":"Jonathan","family":"Barratt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9226-8713","authenticated-orcid":true,"given":"Markus","family":"Jerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","volume":"38","author":"Schena","year":"2018","journal-title":"Semin Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.12688\/f1000research.7352.1","volume":"5","author":"Lai","year":"2016","journal-title":"F1000Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e91756","DOI":"10.1371\/journal.pone.0091756","volume":"9","author":"Moriyama","year":"2014","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/j.ekir.2020.08.009","volume":"5","author":"Barratt","year":"2020","journal-title":"Kidney Int Rep"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1080\/1744666X.2023.2206119","volume":"19","author":"Barratt","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1172\/JCI74475","volume":"124","author":"Kiryluk","year":"2014","journal-title":"J Clin Invest"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/ki.2011.501","volume":"81","author":"Boyd","year":"2012","journal-title":"Kidney Int"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1172\/JCI45563","volume":"121","author":"McCarthy","year":"2011","journal-title":"J Clin Invest"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.semnephrol.2018.05.020","volume":"38","author":"Coppo","year":"2018","journal-title":"Semin Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/iji.12561","volume":"49","author":"Selvaskandan","year":"2022","journal-title":"Int J Immunogenet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1681\/ASN.2006060658","volume":"17","author":"Smith","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1172\/JCI5535","volume":"104","author":"Tomana","year":"1999","journal-title":"J Clin Invest"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1053\/j.ajkd.2011.03.024","volume":"58","author":"Feehally","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"ref17","first-page":"694","volume":"74","author":"Berger","year":"1968","journal-title":"J Urol Nephrol (Paris)"},{"key":"ref18","unstructured":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1\u2013S276."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"FRD14","DOI":"10.2217\/frd-2021-0009","volume":"1","author":"Del Vecchio","year":"2021","journal-title":"Future Rare Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.34067\/KID.0007192020","volume":"5","author":"Cunningham","year":"2021","journal-title":"Kidney360"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"ref23","unstructured":"Kidney Disease: Improving Global Outcomes Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:139\u2013274."},{"key":"ref24","unstructured":"Kinpeygo (budesonide) [European summary of product characteristics]. Bad Vilbel; STADA Arzneimittel AG; 2024. Available from: https:\/\/www.ema.europa.eu\/documents\/product-information\/kinpeygo-epar-product-information_en.pdf. Accessed July 22, 2024."},{"key":"ref25","unstructured":"Tarpeyo (budesonide) [US prescribing information]. Stockholm; Calliditas Therapeutics AB; 2024. Available from: https:\/\/www.tarpeyo.com\/prescribinginformation.pdf. Accessed July 22, 2024."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1093\/ndt\/gfr052","volume":"26","author":"Smerud","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","volume":"103","author":"Barratt","year":"2022","journal-title":"Kidney Int"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.ekir.2022.01.1073","volume":"7","author":"Mathur","year":"2022","journal-title":"Kidney Int Rep"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Barratt J, Kooienga L, Agha I, et al. Updated interim results of a phase 1\/2 study of BION-1301 in patients with IgA nephropathy. European Renal Association (ERA). Milan, Italy, 2023, Abstract 4337. Available from: https:\/\/academic.oup.com\/ndt\/article\/38\/Supplement_1\/gfad063c_4337\/7196269. Accessed June 14, 2024.","DOI":"10.1093\/ndt\/gfad063c_4337"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"ref33","unstructured":"Tumlin JA, Singh H, Cortazar FB, et al. Povetacicept, an enhanced dual BAFF\/APRIL antagonist, in autoantibody-associated glomerulonephritis (GN). American Society of Nephrology Kidney Week. Philadelphia, PA, USA, 2023, TH-PO1125. Available from: https:\/\/www.asn-online.org\/education\/kidneyweek\/2023\/program-abstract.aspx?controlId=3977579. Accessed June 14, 2024."},{"key":"ref34","unstructured":"Alpine Immune Sciences Inc. An open-label study of povetacicept (ALPN-303) in autoimmune kidney diseases (RUBY-3). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05732402. Accessed June 14, 2024."},{"key":"ref35","unstructured":"RemeGen Co Ltd. A study of telitacicept in patients with primary IgA nephropathy. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05799287. Accessed June 14, 2024."},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Floege J, Lafayette R, Barratt J, et al. Felzartamab (anti-CD38) in patients with IgA nephropathy\u2014interim results from the IGNAZ study. European Renal Association (ERA). Stockholm, Sweden, 2024, Abstract 425. Available from: https:\/\/academic.oup.com\/ndt\/article\/39\/Supplement_1\/gfae069-0139-425\/7678088. Accessed June 14, 2024.","DOI":"10.1093\/ndt\/gfae069.139"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Barratt J, Rovin B, Zhang H, et al. Efficacy and safety of iptacopan in IgA nephropathy: results of a randomized double-blind placebo-controlled phase 2 study at 6 months. ISN World Congress of Nephrology (WCN). Kuala Lumpur, Malaysia, 2022, POS\u2013546. Available from: https:\/\/www.kireports.org\/article\/S2468-0249(22)00577-0\/fulltext. Accessed June 14, 2024.","DOI":"10.1016\/j.ekir.2022.01.577"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Barratt J, Fl\u00f6ge J, Duggal V, et al. IMAGINATION: a global phase 3 trial of RO7434656, an antisense oligonucleotide inhibitor of complement factor B, in IgA nephropathy. American Society of Nephrology (ASN) Kidney Week. Philadelphia, PA, USA, 2023, SA\u2013PO885. Available from: https:\/\/medically.roche.com\/content\/dam\/pdmahub\/restricted\/haematology\/asn-kidney-week-2023\/ASN-Kidney-Week-2023-poster-barratt-IMAGINATION-A-global-phase-3-trial.pdf. Accessed June 14, 2024.","DOI":"10.1681\/ASN.20233411S1974a"},{"key":"ref39","unstructured":"Barbour SJ, Makris A, Hladunewich M, et al. An exploratory trial of an investigational RNA therapeutic, IONIS-FB-LRx, for treatment of IgA nephropathy: new interim results. American Society of Nephrology (ASN) Kidney Week. Philadelphia, PA, USA, 2023, SA\u2013PO926. Available from: https:\/\/dam.ionisph.com\/portals\/9s1vyd3c\/ASN-2023_An-Exploratory-Trial-of-IONIS-FB-lrx. Accessed June 14, 2024."},{"key":"ref40","unstructured":"Barratt J, Rocha Castilla JL, Roccatello D, Garlo K, Rice K, Lafayette R. Efficacy and safety of ravulizumab in a phase 2 randomized controlled trial in IgA nephropathy. American Society of Nephrology (ASN) Kidney Week. Philadelphia, PA, USA, 2023, TH\u2013PO1127. Available from: https:\/\/www.asn-online.org\/education\/kidneyweek\/2023\/program-abstract.aspx?controlId=3979029. Accessed June 14, 2024."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/ckj\/sfab294","volume":"15","author":"Bruchfeld","year":"2022","journal-title":"Clin Kidney J"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"EMPA-KIDNEY Collaborative Group. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024;12(1):51\u201360. doi:10.1016\/S2213-8587(23)00322-4","DOI":"10.1016\/S2213-8587(23)00322-4"},{"key":"ref44","unstructured":"Filspari (sparsentan) [US prescribing information]. San Diego; Travere Therapeutics Inc; 2023. Available from: https:\/\/www.filspari.com\/igan\/filspari-prescribing-information.pdf. Accessed July 22, 2024."},{"key":"ref45","unstructured":"Filspari (sparsentan) [Summary of product characteristics]. Vifor France; 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/filspari-epar-product-information_en.pdf. Accessed July 22, 2024."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/00003088-200443120-00003","volume":"43","author":"Edsbacker","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"224","DOI":"10.14227\/DT300423P224","volume":"30","author":"Dressman","year":"2023","journal-title":"Dissolution Technol"},{"key":"ref48","unstructured":"Entocort (budesonide) [Summary of product characteristics]. Wellingore; Tillots Pharma UK Ltd; 2023. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/872\/smpc#gref. Accessed July 22, 2024."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s40262-013-0078-1","volume":"52","author":"Allen","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.semnuclmed.2011.10.004","volume":"42","author":"Szarka","year":"2012","journal-title":"Semin Nucl Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"E396","DOI":"10.1055\/a-1073-7653","volume":"8","author":"O\u2019Grady","year":"2020","journal-title":"Endosc Int Open"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"105812","DOI":"10.1016\/j.ejps.2021.105812","volume":"162","author":"Vinarov","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1007\/s11095-008-9580-9","volume":"25","author":"Ibekwe","year":"2008","journal-title":"Pharm Res"},{"key":"ref54","unstructured":"Dressman, J, Philipson, R, Barratt, J. Comparison of the dissolution profile of Nefecon with three other commercially available oral formulations of budesonide: Implications for interchangeability. IIgANN, Tokyo, Japan, 2023."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.kint.2023.11.003","volume":"105","author":"Wimbury","year":"2023","journal-title":"Kidney Int"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Molyneux K, Nawaz N, Taylor S, Barratt J. Treatment with Nefecon reduces circulating levels of galactose-deficient IgA1 in patients with IgA nephropathy in the NefIgArd clinical trial. American Society of Nephrology Kidney Week. Orlando, FL, USA, 2022, SA-PO654. Available from: https:\/\/www.asn-online.org\/education\/kidneyweek\/2022\/program-abstract.aspx?controlId=3770895. Accessed 22 July, 2024.","DOI":"10.1681\/ASN.20223311S1783d"},{"key":"ref57","unstructured":"Jerling M Systemic GCS exposure from NEFECON administration, estimated from suppression of endogenous cortisol production. American Society of Nephrology Kidney Week. Washington, DC, USA, 2019, TH-PO1029. Available from: https:\/\/www.asn-online.org\/education\/kidneyweek\/2019\/program-abstract.aspx?controlId=3236815. Accessed July 22, 2024."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"105678","DOI":"10.1016\/j.intimp.2019.105678","volume":"74","author":"Yang","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0091-6749(80)90153-0","volume":"65","author":"Chiang","year":"1980","journal-title":"J Allergy Clin Immunol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.1840060204","volume":"6","author":"Hanson","year":"1986","journal-title":"Hepatology"}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/94664","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/94664","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:20:35Z","timestamp":1722385235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/insights-on-nefecon-a-targeted-release-formulation-of-budesonide-and-i-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":61,"URL":"https:\/\/doi.org\/10.2147\/dddt.s383138","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}